摘要
随着转移性肾癌(metastatic RCC,mRCC)治疗方式的不断改进,特别是靶向药物治疗的出现,mRCC患者带瘤生存率显著提高、生存期明显延长,被公认为肾癌预后不良因素的骨转移越来越常见。mRCC患者中20%~35%会出现骨转移,并会导致病理性骨折、脊髓受压等骨相关事件(skeletal related events,SREs)的发生,85%的骨转移患者生存期内至少经历2项SREs相关并发症,严重影响患者的生活质量并且加大治疗的难度。目前肾癌骨转移缺少指南与规范化的诊治方案,骨转移患者临床表现多样且治疗涉及多学科,因此需要重视肾癌骨转移患者的个体化治疗,采用合适的治疗方式降低患者SREs的发生率,在改善生活质量的基础上进一步延长患者生存期。
With the continuous improvement of the treatment of metastatic renal cell carcinoma（mRCC）,especially the appearance of targeted drugs,the survivor with tumor rate and overall survival significantly improved,but bone metastasis which is the well-known poor prognostic factor has become more and more common.About20%-35% of patients with mRCC have bone metastasis which can cause skeletal related events（SREs）,such as pathologic fracture and spinal cord compression.About 85% of patient with mRCC may experience SREs related complications in their life with a mean number of〉2 events per patient.Bone metastasis significantly decreases the patient＇s quality of life and increases the difficulty of treatment.Nowadays the treatment for RCC with bone metastasis involves many disciplines and still lacks of guideline,so further improvements are needed in the individual treatment modalities to reduce the incidence of SREs thereby improving quality of life and prolonging lifetime.
作者
王林辉
董毅
WANG Linhui;DONG Yi(Department of Urology, Changzheng Hospital, Navy Military Medical University, Shanghai, 200003, Chin)
出处
《临床泌尿外科杂志》
2018年第5期337-341,共5页
Journal of Clinical Urology
基金
国家自然科学基金重点项目(编号281730073)
第二军医大学精准医学转化应用研究专项(编号2017JZ22)
关键词
肾细胞癌
骨转移
骨相关事件
个体化
多学科治疗
renal cell carcinoma
bone metastasis
skeletal related events
individual
multiple disciplinarytherapy
